Open-label, Non Comparative, Multi-center Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Oral Miglustat as a Maintenance Therapy After a Switch From Enzyme Replacement Therapy in Adult Patients With Stable Type 1 Gaucher Disease
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Miglustat (Primary)
- Indications Gaucher's disease type I
- Focus Registrational; Therapeutic Use
- Sponsors Actelion Pharmaceuticals
- 24 Oct 2018 Results published in the ClinicalTrials.gov Trial Registry
- 24 Oct 2018 Germany, Hungary, Italy were planned locations according to ClinicalTrials.gov registry
- 04 Apr 2014 New trial record